Product menu

Shingles can lead to serious and long-lasting complications:1*

Postherpetic neuralgia (PHN)

  • Affects up to 30% of patients with shingles2
  • Characterized by long-lasting nerve pain that can persist for months to years1

Herpes zoster ophthalmicus

  • Affects up to 25% of patients with shingles1
  • Can lead to ophthalmic complications and, in rare cases, vision loss1,3

* SHINGRIX is not indicated for the prevention of primary varicella infection or for the treatment of HZ or PHN or ophthalmic complications.

PREV
NEXT

Shingles and its pain were shown to impact quality of life4,5*

At recruitment, out of the 261 eligible participants, 218 (83.5%) reported moderate to severe pain (score ≥3 out of 10), and only 13 (5%) reported having no pain.

Impact of shingles on QoL

Impact of shingles on QoL graph
NA

Adapted from Drolet, et al.5

SHINGRIX is not indicated for the treatment of HZ or its complications, such as PHN.

QoL = quality of life.

* A Canadian multicentre prospective study conducted from October 2005 to July 2006, 261 outpatients aged 50 years or older with herpes zoster were recruited from the clinical practices of 83 physicians within 14 days after rash onset. The Zoster Brief Pain Inventory was used to measure severity of pain and interference with activities of daily living because of pain. The EuroQol EQ-5D assessment tool was used to measure quality of life. These outcomes were assessed at recruitment and on Days 7, 14, 21, 30, 60, 90, 120, 150, and 180 following recruitment.

Graph icon

Efficacy data for SHINGRIX4

Vaccine efficacy profile was studied in subjects ≥50 years old (ZOE-50) and subjects ≥70 years old (ZOE-70). SHINGRIX efficacy profile was also studied in two immunocompromised patient populations aged ≥18 years.4

Learn more
Patient icon

Start the conversation about shingles risk with your patients

Nearly everyone ≥50 years old should be protected against shingles.2

Learn more
Checkmark icon

SHINGRIX: Recommendations from NACI

Review the recommendations on the use of SHINGRIX by the National Advisory Committee on Immunization (NACI).2

Learn more

References:

  1. Harpaz R, et al. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1–30.
  2. National Advisory Committee on Immunization (NACI). Statement on the recommended use of herpes zoster vaccine. Can Commun Dis Rep 2010;36(ACS-1):1–19.
  3. Volpi A. Severe complications of herpes zoster. Herpes 2007;14 Suppl 2:35–39.
  4. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.
  5. Drolet, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ 2010;182(16):1731–1736.
  6. Government of Canada. Herpes zoster (shingles) vaccine: Canadian Immunization Guide. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-8-herpes-zoster-(shingles)-vaccine.html. Accessed February 13, 2023.

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK Group of companies or its licensor.

10572 | 05/24

Open cookie banner
Hide cookie banner